AltrixBio
AltrixBio is a biotech company focused on developing innovative solutions for diabetes management, including the revolutionary LuCI™ pill that mimics the effects of gastric bypass surgery. Founded in 2019, the company leverages research from Harvard Medical School to create minimally invasive, safe, and effective treatments for type-2 diabetes and related metabolic disorders.
Industries
Nr. of Employees
small (1-50)
AltrixBio
325 Vassar Street, Suite 2A, Cambridge MA 02139
Products
Oral transient luminal coating formulation (repurposed drug for modulation of nutrient absorption)
A repurposed oral formulation designed to transiently coat the proximal small intestine mucosa to reduce nutrient contact with the bowel and lower postprandial glucose via local action and limited systemic exposure.
Oral transient luminal coating formulation (repurposed drug for modulation of nutrient absorption)
A repurposed oral formulation designed to transiently coat the proximal small intestine mucosa to reduce nutrient contact with the bowel and lower postprandial glucose via local action and limited systemic exposure.
Services
Engagement with physicians and investigators to support planning and recruitment for first-in-human clinical trials and investigator-led studies.
Engagement with physicians and investigators to support planning and recruitment for first-in-human clinical trials and investigator-led studies.
Expertise Areas
- Biomaterials-based oral drug delivery
- GI-targeted therapeutics
- Preclinical metabolic and pharmacology studies
- Drug repurposing for new indications
Key Technologies
- Luminal coating (GI-adhering) formulations
- Acid- and enzyme-resistant oral formulations
- Biomaterials formulation
- Mucosal delivery of biologics
News & Updates
Ali Tavakolli MD discusses LuCI™ at the ATTD 2021 Tech Fair, highlighting its potential as a non-invasive alternative to gastric bypass surgery for diabetes treatment.
Brigham scientists reformulate pill to reverse type 2 diabetes, showcasing the innovative approach of AltrixBio.
AltrixBio was recognized as one of the Top 10 Biotech Startups of 2021 by Pharma Tech Outlook, highlighting its innovative contributions to biotech.
Ali Tavakolli MD discusses LuCI™ at the ATTD 2021 Tech Fair, highlighting its potential as a non-invasive alternative to gastric bypass surgery for diabetes treatment.
Brigham scientists reformulate pill to reverse type 2 diabetes, showcasing the innovative approach of AltrixBio.
AltrixBio was recognized as one of the Top 10 Biotech Startups of 2021 by Pharma Tech Outlook, highlighting its innovative contributions to biotech.